Santen Pharmaceutical Co., Ltd. (SNPHY)
SNPHY Stock Price Chart
Explore Santen Pharmaceutical Co., Ltd. interactive price chart. Choose custom timeframes to analyze SNPHY price movements and trends.
SNPHY Company Profile
Discover essential business fundamentals and corporate details for Santen Pharmaceutical Co., Ltd. (SNPHY) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - General
IPO Date
31 Aug 2011
Employees
3.74K
Website
https://www.santen.comCEO
Takeshi Ito
Description
Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.
SNPHY Financial Timeline
Browse a chronological timeline of Santen Pharmaceutical Co., Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 4 Feb 2026
Upcoming earnings on 5 Nov 2025
Earnings released on 4 Aug 2025
Earnings released on 13 May 2025
EPS came in at $0.18 , while revenue for the quarter reached $531.04M , beating expectations by +7.17%.
Dividend declared on 31 Mar 2025
A dividend of $0.09 per share was announced, adjusted to $0.09. The dividend was paid on 10 Jul 2025.
Earnings released on 6 Feb 2025
Earnings released on 7 Nov 2024
Dividend declared on 30 Sept 2024
A dividend of $0.08 per share was announced, adjusted to $0.08. The dividend was paid on 16 Dec 2024.
Earnings released on 6 Aug 2024
EPS came in at $0.18 , while revenue for the quarter reached $465.52M .
Earnings released on 9 May 2024
EPS came in at $0.00 , while revenue for the quarter reached $521.64M .
Dividend declared on 27 Mar 2024
A dividend of $0.07 per share was announced, adjusted to $0.07. The dividend was paid on 11 Jul 2024.
Earnings released on 8 Feb 2024
EPS came in at $0.16 , while revenue for the quarter reached $491.28M .
Earnings released on 31 Dec 2023
EPS came in at $0.15 , while revenue for the quarter reached $550.61M .
Dividend declared on 28 Sept 2023
A dividend of $0.07 per share was announced, adjusted to $0.07. The dividend was paid on 15 Dec 2023.
Earnings released on 30 Jun 2023
EPS came in at $0.19 , while revenue for the quarter reached $500.90M .
Earnings released on 31 Mar 2023
EPS came in at $0.02 , while revenue for the quarter reached $598.11M .
Dividend declared on 30 Mar 2023
A dividend of $0.08 per share was announced, adjusted to $0.08. The dividend was paid on 13 Jul 2023.
Earnings released on 31 Dec 2022
EPS came in at $0.12 , while revenue for the quarter reached $546.37M .
Earnings released on 30 Sept 2022
EPS came in at -$0.52 , while revenue for the quarter reached $438.35M .
Dividend declared on 29 Sept 2022
A dividend of $0.08 per share was announced, adjusted to $0.08. The dividend was paid on 15 Dec 2022.
Earnings released on 30 Jun 2022
EPS came in at $0.12 , while revenue for the quarter reached $482.14M .
Earnings released on 31 Mar 2022
EPS came in at $0.16 , while revenue for the quarter reached $576.19M .
Dividend declared on 29 Mar 2022
A dividend of $0.09 per share was announced, adjusted to $0.09. The dividend was paid on 12 Jul 2022.
Earnings released on 31 Dec 2021
EPS came in at $0.11 , while revenue for the quarter reached $582.88M .
Earnings released on 30 Sept 2021
EPS came in at $0.16 , while revenue for the quarter reached $572.53M .
Dividend declared on 28 Sept 2021
A dividend of $0.10 per share was announced, adjusted to $0.10. The dividend was paid on 15 Dec 2021.
Earnings released on 30 Jun 2021
EPS came in at $0.17 , while revenue for the quarter reached $584.72M .
Earnings released on 31 Mar 2021
EPS came in at -$0.32 , while revenue for the quarter reached $613.55M .
Dividend declared on 29 Mar 2021
A dividend of $0.10 per share was announced, adjusted to $0.10. The dividend was paid on 13 Jul 2021.
Earnings released on 31 Dec 2020
EPS came in at $0.17 , while revenue for the quarter reached $608.53M .
Earnings released on 30 Sept 2020
EPS came in at $0.18 , while revenue for the quarter reached $581.11M .
Dividend declared on 28 Sept 2020
A dividend of $0.10 per share was announced, adjusted to $0.10. The dividend was paid on 15 Dec 2020.
SNPHY Stock Performance
Access detailed SNPHY performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.